At a glance

ClinicalIndex Comparison Record

Early Ph 1Active· 12 enrolled

Drug / intervention

Venetoclaxdrug

Likely dose

Venetoclax 100mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05386576

NCT05386576Early Ph 1Active

Compare CT.gov

Venetoclax in Combination With Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center·interventional·Posted May 23, 2022·Updated Jun 16, 2026

In Brief

A Early Phase 1 clinical trial evaluating Venetoclax for Acute Lymphoblastic Leukemia. Active but no longer recruiting, targeting 12 participants across 1 site.

Detailed Summary

The researchers are doing this study to find out whether combining venetoclax with several different standard chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) in children is safe and effective in adults with newly diagnosed ALL. Participants in this study will be under the age of 60, and they will have T- or B-cell ALL.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAcute Lymphoblastic Leukemia

CountriesUnited States

CollaboratorsGenentech, Inc.

Timeline

Early Ph 1Active

20232024202520262027

First PostedMay 2022

Enrollment StartJun 2022

TodayJul 2026

Primary CompletionMay 2027

First PostedMay 23, 2022

Enrollment StartJun 16, 2022

Primary CompletionMay 1, 2027

TodayJul 1, 2026

Enrollment to primary: 4.9 yearsPosted 4.1 years agoPrimary completion in 10 months

Interventions

Venetoclaxdrug

During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28. During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42.